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Abstract 
Background: Left ventricular (LV) mechanics are impaired in patients with severe aortic 
stenosis (AS); however, transcatheter aortic valve implantation (TAVI) may positively affect LV 
mechanics. Assessed herein is the performance of the SAPIEN 3 transcatheter heart valve (THV) 
and the effect of TAVI on LV function recovery, as assessed by global longitudinal strain (GLS). 
 Methods: A subset of patients from the SOURCE 3 registry (n = 276) from 16 European centers 
received SAPIEN 3 balloon-expandable THV. Echocardiography was performed at baseline, 
post-procedure, and at 1 year, including assessment of GLS using standard two-dimensional 
images, and was analyzed in a core laboratory. Paired analyses between baseline and discharge, 
baseline and at 1 year were conducted. 
Results: Hemodynamic parameters were improved after TAVI and sustained to 1 year. At 1 year, 
the rate of moderate to severe paravalvular leaks (PVL), and moderate to severe mitral and 
tricuspid regurgitations were 1.8%, 1.7%, and 8.0%, respectively. The discharge GLS (–15.6 ± 
5.1; p = 0.004; n = 149) improved significantly from baseline (–15.1 ± 4.8) following TAVI. This 
improvement was sustained at 1 year compared with baseline (–17.0 ± 4.6, p < 0.001; n = 100). 
Conversely, LV ejection fraction (LVEF) did not significantly change following TAVI (p = 
0.47). 
Conclusions: Following TAVI with a third-generation THV, valve performances were good at 1 
year with low PVL rate. The LV mechanics improved immediately after the procedure and were 
maintained at 1 year. These findings demonstrate the benefit of TAVI on LV mechanics, and 
suggests that GLS may be superior to LVEF in assessing this benefit. 
Clinicaltrial.gov number: NCT02698956. 
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Introduction 
Degenerative aortic stenosis (AS) is one of the most prevalent cardiovascular diseases in 
developed countries. Over the past decade, transcatheter aortic valve implantation (TAVI) has 
emerged as the therapy of choice for patients with AS considered inoperable or at high surgical 
risk [1, 2]. TAVI has improved the prognosis of these patients. And, as transcatheter heart valves 
(THV) have evolved, patients who had received TAVI suffered fewer complications.  
 Aortic stenosis induces a series of adaptive responses. It generates a pressure overload 
that alters left ventricular (LV) geometry and performance; although, LV volume and LV ejection 
fraction (LVEF) may be preserved, even in advanced stages of the disease [3]. The most 
important changes caused by the pressure overload include hypertrophic remodeling [4], diastolic 
dysfunction [5, 6], and impaired contractility [7].  
Patients with AS who are treated with TAVI can experience relief from this pressure 
overload that is reflected in changes in LV strain [4]. The immediate result of TAVI is often an 
acute decrease in transvalvular gradient, leading to an improvement of LV mechanics. This could 
be a precursor to, or a reverse in, remodeling, possibly leading to a reduction in LV mass and an 
improvement in long-term diastolic function. 
Studies have demonstrated that strain (GLS) imaging is the most appropriate method to 
evaluate subtle changes in myocardial function that occur in patients with AS [8, 9]. Additionally, 
global longitudinal strain (GLS) is independently predictive of mortality [10]. In a recently 
published study of 92 patients treated in Europe with either the self-expanding CoreValve 
(Medtronic, Minneapolis, MN, USA) or the mechanically expanded Lotus valve (Boston 
Scientific, Natick, MA, USA), TAVI was associated with an immediate improvement in LV 
mechanics, as demonstrated by GLS increase; although LV systolic function remained unaltered 
[4].  
The literature on post implantation LV mechanics is limited. The impact of TAVI on LV 
mechanics using GLS in patients who received the SAPIEN 3 (Edwards Lifesciences; Irvine, CA, 
USA) balloon-expandable, transcatheter valve at 1 year follow-up were analyzed.  
 
Methods 
Study population 
Patients with symptomatic, severe AS were implanted with the third-generation, balloon-
expandable SAPIEN THV (SAPIEN 3). The selection of patients was based on a clinical 
consensus of the Heart Team. A subset of patients from the SOURCE 3 registry had planned, per 
protocol, to have their echocardiograms reviewed by an independent central echocardiography 
 core laboratory (ECL; Ramon y Cajal, Madrid). Patients had echocardiograms at baseline, 
discharge, and at 1 year after implantation. 
 
Intervention and purpose 
The SAPIEN 3 Aortic Bioprosthesis European Outcome (SOURCE 3) is a European, 
post-approval multicenter, observational registry, aimed to evaluate the safety and performance 
of the SAPIEN 3 THV under real-world conditions. The full cohort of 30-day and 1-year results 
had been published previously [11, 12]. A protocol was developed for this echocardiographic 
sub-study. It was approved by the local ethics committees and the respective health authorities in 
participating countries (France, Germany, United Kingdom, and Italy). All patients provided 
written, informed consent before the study commenced. 
Clinical outcomes (cardiac death and disabling stroke to 1 year and life-threatening 
bleedings to 30 days) were adjudicated by a clinical event committee. 
Patients had two-dimensional (2D) transthoracic echocardiograms according to the 
protocol. The sites sent the echocardiograms to the core laboratory for comprehensive evaluation 
of hemodynamic performance of valve and LV function. The protocol stipulated multiple 
echocardiographic measurements before and after prosthesis implantation, as well as 
quantification of LV mechanics, measuring LV strain with standard 2D imaging (Image Arena 
and CPA package, TomTec Imaging System). The assessment of GLS was done using averages 
of measures taken from images on three views: apical 4-, 2- and 3-chamber views in an 18-
segment LV model. To obtain LV strain measurements, endocardial contour needed to be 
manually outlined, after which the system generated the myocardial perimeter on the end systolic 
frame. Images of measures in a patient with baseline, discharge, and 1-year measures are 
displayed in supplementary files (Suppl. Image 1 and 2). 
Two experienced cardiologists examined all echocardiographic data. Intraoperatory 
aortograms were also performed during valve implantation by many participating sites. A 
hemodynamic cardiologist from the core laboratory, who was blinded to the echocardiographic 
results, evaluated these studies.  
 The aim of the study was to evaluate the impact of TAVI on myocardial longitudinal LV 
systolic strain in patients with severe, degenerative AS. Additionally, the ECL evaluated 
hemodynamic parameters. 
 
Statistical analysis 
Study staff at participating centers entered echocardiographic data into an electronic 
capture system. The Sponsor monitored it before it was sent to the ECL. Comparisons of baseline 
and procedural characteristics between the subset of patients analyzed and the rest of the 
SOURCE 3 cohort were conducted using the Wilcoxon sum rank test for the continuous variables 
and the Fisher exact test for categorical variables. 
Echocardiographic parameters were compared between discharge and at 1 year, using 
paired analysis with the Wilcoxon sum rank test. Mean gradient, effective orifice area (EOA), 
and GLS were compared (baseline vs. discharge and baseline vs. 1 year), using a paired analysis 
with the t test. 
 
Results 
Baseline and procedural data 
A total of 276 patients were enrolled in the echocardiographic analysis between July 2014 
and October 2015 in 16 European centers. In summary, patient baseline characteristics were a 
mean age of 80.8 years and a mean EuroSCORE II of 4.6 ± 3.98 (Table 1). The latter was 
statistically lower than the mean EuroSCORE II of the SOURCE 3 patients not included in this 
sub-analysis (p = 0.002), as more Echo patients had a logistic EuroSCORE of < 10%, compared 
with other patients of the SOURCE 3 cohort (35.0% vs. 28.2%; p = 0.041), and fewer echo 
patients had a logistic EuroSCORE of > 30% compared with other patients of the cohort (10.2% 
vs. 16.6%; p = 0.011). Most other baseline clinical characteristics and comorbidities were 
comparable between the subset of patients analyzed and the rest of the SOURCE 3 cohort, except 
for hypertension (72.1% in the echo patients vs. 83.4% in other SOURCE 3 patients; p < 0.001), 
 congestive heart failure (46.7% vs. 34.6%; p < 0.001), and mitral regurgitation of moderate or 
severe grade (9.2% vs. 14.8%; p = 0.015). 
Most TAVI procedures were performed using a transfemoral approach (87.3%), with the 
SAPIEN 3 THV 23 mm (40.6%), 26 mm (36.2%), and 29 mm (23.2%). 
An intraprocedural angiography was retrieved in 103 patients; most were adjudicated as 
grade 1, but a small percentage were considered grade 2 (Table 2).  
In terms of clinical outcomes, the cohort had a 30-day and 1-year mortality rate of 1.5% 
and 5.4%, respectively. The cardiac mortality rate was 0.7% and 3.1%, at 30 days and 1 year, 
respectively. The disabling stroke rate was 0.7% and 1.1%, at 30 days and 1 year, respectively. 
The life-threatening bleeding rate was 5.4% at 30 days. 
 
Echocardiographic parameters  
Aortic regurgitation severity was predominantly grade 1, using both the Seller and Valve 
Academic Research Consortium-2 criteria (93.2% each; Table 3). Other echocardiographic 
parameters are presented in Table 4. 
 
Effective orifice area and mean gradient 
The TAVI treatment significantly improved the mean EOA from 0.8 ± 0.3 cm2 at baseline 
to 1.6 ± 0.6 cm2 at discharge (Fig. 1, Table 4). This improvement was sustained at 1 year (1.5 ± 
0.5 cm2; p < 0.001 compared with baseline). Similarly, the mean gradient was decreased 
following the THV treatment from 41.2 ± 14.6 mmHg at baseline to 12.2 ± 5.3 mmHg at 
discharge (p < 0.001), and was maintained at 1 year (12.7 ± 5.8 mmHg; p < 0.001 compared with 
baseline). 
 
Total aortic regurgitation and paravalvular leak  
Few patients had total aortic regurgitation (TAR) at discharge; it was moderate severity in 
5 (2.1%) patients and severe in 2 (0.8%) patients (Fig. 2). At 1 year, 3 (1.7%) patients had 
 moderate TAR; no severe TAR was observed (Fig. 2). Similarly, few severe to moderate PVLs 
were present at discharge (2.9%) and 1 year (1.8%; Fig. 2). 
 
Mitral and tricuspid regurgitation 
At discharge, 2 patients had moderate severity mitral regurgitation and 2 had severe mitral 
regurgitation (Fig. 3). At 1 year, 3 patients had moderate mitral regurgitation. The percentage of 
mild mitral regurgitation was significantly lower at 1 year compared with discharge (20.3% vs. 
28.3%, respectively; p = 0.011). 
Similarly, 6 patients suffered from tricuspid regurgitation of moderate severity at 
discharge and 3 others presented with severe tricuspid regurgitation (Fig. 3). At 1 year, 7 patients 
presented with moderate tricuspid regurgitation and 4 patients with severe tricuspid regurgitation. 
The percentage of mild mitral tricuspid regurgitation was significantly lower at 1 year compared 
with discharge (22.1% vs. 40.1%, respectively; p = 0.006). 
 
Global longitudinal strain analysis 
The left ventricle peak systolic longitudinal strain significantly improved after TAVI (Fig. 
4A), and significantly increased at 1 year compared with baseline (–17.0 ± 4.6; p = 0.001). No 
change was observed on the LVEF (Fig. 4B).  
 
Discussion  
This echocardiographic evaluation performed in a real-world setting in European patients 
with severe AS who received a transcatheter SAPIEN 3 demonstrated good valve performance, 
low PVL of moderate to severe grade at 1 year, and statistically significant improvement in LV 
function as assessed by GLS. No change in LVEF was observed. 
 
Population studied  
 It was thought that the population analyzed in the present study was representative of 
patients with severe AS and were usually referred for the TAVI procedure. Demographic and 
clinical parameters at baseline were comparable with those of the entire SOURCE 3 cohort, 
except for a slightly lower surgical risk score in the SOURCE 3 cohort. 
 
Echocardiographic parameters  
A comprehensive echocardiographic assessment from randomized trials, including the 
PARTNER 2 SAPIEN 3 registry, presented comparable mean gradient and EOA at discharge or 
at 30 days (mean gradient of 11.18 ± 4.35 mmHg and EOA of 1.66 ± 0.38 cm2; n = 1470) as 
assessed by the ECL [13].  
One potential disadvantage of TAVI is an increased incidence of post-procedural aortic 
regurgitation, which is an independent predictor of short- and long-term mortality, and which 
may have a negative impact on LV myocardial recovery [14, 15]. The presence of post-
procedural PVL appears to limit LV structural and functional recovery [16]. Post-procedural PVL 
was rare at 1 year and no patients presented with severe PVL.  
 
Left ventricular strain analysis 
The first signs of reverse LV remodeling at discharge were observed, and were sustained 
for 1 year. A significant increase in GLS was numerically modest, but statistically significant, 
observed at discharge and not only sustained, but also improved at 1 year. This result represents 
signs of reverse remodeling, as previously reported in TAVI [4, 17] or surgical aortic valve 
replacement studies [7]. Several studies have demonstrated an amelioration in LV mass [18], 
some diastolic ﬁlling parameters [18, 19]1, and left atrial function in patients after TAVI [16, 19]. 
The LVEF is confounded by the positive remodeling of the left ventricle, i.e., regression of LV 
concentric hypertrophy; LVEF is not a good marker of LV intrinsic myocardial function. 
 
Limitations of the study 
 A few patients were not evaluable, mainly because their echocardiographs were of poor 
quality, so there may have been selection bias.  
One of the limitations of the study is loss to follow-up of some patients. The reason for 
this was due to the multicenter recruitment: many patients travelled far to have the TAVI 
procedure and could not return for the 12-month echo. However, updates were received from the 
sites and local phone calls related to the absence of mortality in non-returning patients. In 
addition, some studies were excluded from analysis due to the poor quality of examinations.  
This SOURCE 3 sub-study was designed as a purely echocardiographic study. 
Consequently, no clinical parameters were collected in follow-up, including those affecting 
quality of life data. Further studies are required to seek correlation between echocardiographic 
improvement in LV mechanics and clinical response.  
 
Conclusions 
A subset of patients from the SOURCE 3 registry who received the SAPIEN 3 balloon-
expandable THV had improved LV mechanics immediately following the procedure that were 
sustained for 1 year, as determined by standard 2D imaging. The valve performance was good at 
1 year, with a low PVL rate. 
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 Table 1. Baseline characteristics of the SOURCE 3 cohort. 
 
Patients with AS who 
received SAPIEN 3 THV 
(n = 276) 
Patients with AS who 
received SAPIEN 3 
THV, with no ECL 
assessment (n = 1670) 
P  
Demographics and clinical variables 
Age [years], mean ± SD 80.8 ± 7.47 81.7 ± 6.49  0.124 
Age ≥ 80 years 184 (66.7%)  1136 (68.0%) 0.677 
Female 126 (45.7%) 809 (48.4%) 0.399 
Logistic EuroScore, mean ± 
SD 
15.6 ± 10.60, N = 226 18.7 ± 13.46, N = 1558 0.002 
EuroScore II, mean ± SD 4.6 ± 3.98, N = 204 5.7 ± 5.71, N = 1295 0.007 
NYHA class IV 19 (7.0%), N = 272 150 (9.3%), N = 1607 < 0.001 
Hypertension 199 (72.1%)  1392 (83.4%) 0.090 
Dyslipidaemia 136 (49.3%)  918 (55.0%) 0.103 
History of smoking 95 (34.4%) 490 (29.4%), N = 1669 0.117 
Diabetes 70 (25.4%)  504 (30.2%) 0.194 
Coronary artery disease 132 (47.8%)  870 (52.1%) 0.546 
Myocardial infarction 29 (10.5%)  199 (11.9%) 0.414 
Coronary bypass grafting 27 (9.8%)  194 (11.6%), N = 1669 0.001 
Congestive heart failure 129 (46.7%)  577 (34.6%) 0.561 
Renal insufficiency 80 (29.0%)  455 (27.2%) 0.039 
Percutaneous coronary 
intervention 
78 (28.3%)  580 (34.8%), N = 1669 0.124 
Aortic valve severity  
Mitral regurgitation (degree 
moderate to severe) 
24 (9.2), N = 260 224 (14.8), N = 1513 0.015 
Tricuspid regurgitation 
(moderate to severe) 
18 (7.3), N = 245 162 (11.5), N = 1404 0.059 
P values are from the Wilcoxon sum rank test for the continuous variables and the Fisher exact 
test for categorical variables. AS — aortic stenosis; ECL — echocardiology core laboratory; LV 
— left ventricle; NYHA — New York Heart Association; SD — standard deviation; THV — 
transcatheter heart valve 
 
 
 
 Table 2. Procedural characteristics. 
 
 
 
Procedural characteristics 
Patients who received 
echocardiograms (n = 276) 
  
Total procedure time [min] 72.1 ± 52.23 (N=204) 
Total anaesthesia time [min] 127.0 ± 84.71 (n = 127) 
Access approach:  
 Transfemoral 241 (87.3%) 
 Transapical 26 (9.4%) 
 Transaortic 7 (2.5%) 
Implanted valve size [mm]:  
 23 mm 112 (40.6%) 
 26 mm 100 (36.2%) 
 29 mm 64 (23.2%) 
  
Table 3. Aortic regurgitation severity. 
Criteria 
Patients who received intraprocedural 
angiography (n = 103) 
Evaluation with Seller’s criteria 
Grade 1 96 (93.2%) 
Grade 2 7 (6.8%) 
Grade 3 0 (0%) 
Grade 4 0 (0%) 
Evaluation with VARC 2 criteria 
Grade 1 96 (93.2%) 
Grade 2 7 (6.8%) 
Grade 3 0 (0%) 
Grade 4 0 (0%) 
VARC — Valve Academic Research Consortium 
 Table 4. Echocardiographic parameters. 
Parameter 
Baseline 
Mean ± SD (n) 
Discharge 
Mean ± SD (n) 
1 year 
Mean ± SD (n) 
P* (n) 
Baseline vs. 
discharge 
P* (n) 
Discharge vs. 
1 year 
LVEDV [mL] 81.3 ± 36.0 (211) 76.0 ± 36.1 (183) 80.0 ± 33.7 (130) 0.013 (151) 0.316 (85) 
LVESV [mL] 36.3 ± 26.5 (211) 34.8 ± 26.0 (183) 35.5 ± 26.2 (129) 0.028 (151) 0.760 (85) 
LVEDD [cm] 4.8 ± 0.8 (221) 4.7 ± 0.8 (187) 4.7 ± 0.8 (123) 0.109 (162) 0.160 (92) 
LVESD [cm] 3.2 ± 1.0 (210) 3.2 ± 1.00 (183) 3.1 ± 0.9 (119) 0.036 (152) 0.325 (88) 
LVEF [%] 58.6 ± 15.6 (211) 57.5 ± 14.9 (183) 58.8 ± 13.2 (129) 0.471 (151) 0.712 (85) 
LV posterior wall diastolic 1.1 ± 0.2 (219) 1.2 ± 0.2 (187) 1.1 ± 0.2 (120) 0.123 (162) 0.025 (90) 
Interventricular septum diastolic 1.3 ± 0.3 (221) 1.4 ± 0.3 (192) 1.3 ± 0.2 (120) 0.235 (166) 0.210 (93) 
Left atrial volume [mL] 75.6 ± 35.5 (237) 77.4 ± 32.2 (212) 74.9 ± 29.6 (163) 0.754 (186) 0.380 (124) 
AV mean gradient [mmHg] 41.2 ± 14.6 (251) 12.2 ± 5.3 (242) 12.7 ± 5.8 (178) < 0.001 (223) 0.025 (155) 
AV area (EOA) [cm2] 0.8 ± 0.3 (227) 1.6 ± 0.6 (202) 1.5 ± 0.5 (159) < 0.001 (173) 0.007 (120) 
AV velocity time integral 96.7 ± 22.6 (251) 44.0 ± 11.4 (240) 49.6 ± 13.8 (178) < 0.001 (221) < 0.001 (153) 
Mitral annulus velocity [cm/s] 6.1 ± 1.9 (99) 6.2 ± 2.0 (89) 6.5 ± 2.4 (85) 0.911 (47) 0.167 (44) 
E/e’ ratio (filling pressures) 
[mmHg] 
17.9 ± 7.9 (96) 17.2 ± 8.1 (86) 17.8 ± 8.1 (80) 0.920 (44) 0.917 (41) 
Systolic pulmonary pressure 
[mmHg] 
302.2 ± 52.0 (47) 273.2 ± 42.25 (59) 282.2 ± 45.8 (65) 0.843 (14) – 
*P values are from the Wilcoxon sum rank (paired) test. Mean ± standard deviation (SD) presented in the 3 first columns were 
calculated on all values available. AV — atrio-ventricular; EOA — effective orifice area; LVEDD — left ventricular end diastolic 
diameter; LVEF — left ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; LVESD — left ventricular end-
systolic diameter; LVESV — left ventricular end-systolic volume 
 Figure 1. Effective orifice area and mean gradient — paired analyses. 
 
Figure 2. Total aortic regurgitation and paravalvular leak — paired analyses. 
 
Figure 3. Mitral regurgitation and tricuspid regurgitation — paired analyses. 
 
Figure 4. A. Global longitudinal strain analysis; B. Left ventricular ejection fraction; the box plot 
represents the mean ± standard deviation, median, minimum and maximum (whiskers) of the 
global longitudinal strain. P values compare baseline with discharge, and baseline with 1-year 
data using the paired t-test. 
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